In the pivotal Phase 3 VIVID-1 trial, patients treated with Omvoh experienced significant improvement in clinical remission and endoscopic response at one year Among those who achieved clinical ...

Lilly is also developing oral therapies for its gastroenterology pipeline.

Omvoh is a biologic medicine used to treat moderate to severe ulcerative colitis. Ulcerative colitis is an inflammatory bowel disease that causes inflammation in parts of the digestive tract.

Eli Lilly has released histological data from the Phase III VIVID-1 trial showing that its Crohn’s disease therapy Omvoh (mirikizumab) was superior to Johnson & Johnson’s (J&J) Stelara ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved Omvoh for the treatment of moderately to severely active Crohn’s disease, making it ...

FDA Approves Omvoh for Moderately to Severely Active Crohn Disease By Elana Gotkine HealthDay Reporter THURSDAY, Jan. 16, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has ...

Jan. 16, 2025 – The FDA has approved the drug Omvoh for treating adults with moderately to severely active Crohn's disease, a type of chronic inflammatory bowel disease. This marks the second ...

Key approval signals progress in addressing immune-mediated inflammatory diseases. In October 2023, the FDA announced the approval of Omvoh for the treatment of moderately to severely active ...

Lilly (NYSE:LLY) has also applied to have Omvoh approved by the FDA for the treatment of moderately to severely active Crohn's disease. A decision expected in the first half of 2025.

In the pivotal Phase 3 VIVID-1 trial, patients treated with Omvoh experienced significant improvement in clinical remission and endoscopic response at one year Among those who achieved clinical ...